10:57 AM EDT, 10/12/2026 (MT Newswires) -- Pila Pharma (PILA.ST) dosed the first two subjects of its 12-week trial assessing the safety and efficacy of drug candidate XEN-D0501 in obese participants. The PP-CT04 trial is designed to test a within-subject dose titration approach to reach expected therapeutic plasma concentrations of XEN-D0501 that have not been studied before, according to a Monday release. One of the two participants received the active treatment while the other received a placebo, with each dose to be increased individually from 4 milligrams twice daily up to a maximum of 16-mg twice daily, with one week at each level. The Swedish clinical-stage biotech company's trial, conducted in collaboration with Clinical Trial Consultants, is divided into two parts, with the same overall design.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.